Rui Zhao
About Rui Zhao
Rui Zhao is a Senior Principal Scientist at Bristol Myers Squibb with extensive experience in therapeutic antibodies and biopharmaceuticals.
Company
Rui Zhao currently works at Bristol Myers Squibb in Devens, MA, as a Senior Principal Scientist. This role involves high-level responsibilities in the research and development of therapeutic antibodies, crucial to the company's biopharmaceutical advancements.
Title
Rui Zhao holds the title of Senior Principal Scientist at Bristol Myers Squibb. This senior role underscores their expertise in promoting and overseeing significant projects within the biopharmaceutical industry.
Education and Expertise
Rui Zhao achieved a Doctor of Philosophy (Ph.D.) in Protein Chemistry, Proteomics, and Marine Medicine from the Ocean University of China. They also hold a Bachelor's Degree in Pharmacy and a Master's Degree in Biopharmaceutical Science from Shandong University. Zhao's educational background laid a strong foundation for their extensive experience in therapeutic antibody research, cGMP, CMC, and biopharmaceutical manufacturing.
Professional Background
Rui Zhao has held notable positions across multiple biopharmaceutical companies. Prior to their current role, Zhao was a Group Leader/Scientist II at Abpro in Woburn, MA, for 7 months in 2017-2018. From 2010 to 2017, they served as an Associate Group Leader at PPD in Middleton. Before that, Zhao spent 4 years at the University of Wisconsin-Madison as an Associate Researcher. Their career path showcases diverse roles that have built their profound knowledge in the field.
Research and Development Experience
Rui Zhao possesses extensive experience in the research and development of therapeutic antibodies, encompassing their manufacturing and commercialization. Their expertise includes working within biopharmaceutical practices and regulations such as cGMP and CMC, as well as understanding the intricate details of upstream, downstream, and analytical processes in the industry. Zhao's background in these areas makes them a vital asset to the field of biopharmaceuticals.